View in EDS PDF Full Text

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Saved in:
Bibliographic Details
Title: Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
Authors: Kohli MA; Michele A. Kohli (michele.kohli@optum.com) is a director of health economics and outcomes research at Optum in Burlington, Ontario., Farkouh RA; Raymond A. Farkouh is senior director of outcomes research at Pfizer Vaccines Inc., in Collegeville, Pennsylvania., Maschio MJ; Michael J. Maschio is a lead analyst for health economics and outcomes research at Optum in Ontario., McGarry LJ; Lisa J. McGarry is a director of health economics and outcomes research at Ariad Pharmaceuticals Inc., in Cambridge, Massachusetts. At the time of this study, she was a director of health economics and outcomes research at Optum in Boston, Massachusetts., Strutton DR; David R. Strutton is a vice president of outcomes research at Merck in North Wales, Pennsylvania. At the time of this study, he was a vice president of global health and value at Pfizer Inc., Weinstein MC; Milton C. Weinstein is the Henry J. Kaiser Professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health, in Boston.
Source: Health affairs (Project Hope) [Health Aff (Millwood)] 2015 Jul; Vol. 34 (7), pp. 1234-40.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Project Hope Country of Publication: United States NLM ID: 8303128 Publication Model: Print Cited Medium: Internet ISSN: 2694-233X (Electronic) Linking ISSN: 02782715 NLM ISO Abbreviation: Health Aff (Millwood) Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 26135209
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kohli+MA%22">Kohli MA</searchLink>; Michele A. Kohli (michele.kohli@optum.com) is a director of health economics and outcomes research at Optum in Burlington, Ontario.<br /><searchLink fieldCode="AU" term="%22Farkouh+RA%22">Farkouh RA</searchLink>; Raymond A. Farkouh is senior director of outcomes research at Pfizer Vaccines Inc., in Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Maschio+MJ%22">Maschio MJ</searchLink>; Michael J. Maschio is a lead analyst for health economics and outcomes research at Optum in Ontario.<br /><searchLink fieldCode="AU" term="%22McGarry+LJ%22">McGarry LJ</searchLink>; Lisa J. McGarry is a director of health economics and outcomes research at Ariad Pharmaceuticals Inc., in Cambridge, Massachusetts. At the time of this study, she was a director of health economics and outcomes research at Optum in Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Strutton+DR%22">Strutton DR</searchLink>; David R. Strutton is a vice president of outcomes research at Merck in North Wales, Pennsylvania. At the time of this study, he was a vice president of global health and value at Pfizer Inc.<br /><searchLink fieldCode="AU" term="%22Weinstein+MC%22">Weinstein MC</searchLink>; Milton C. Weinstein is the Henry J. Kaiser Professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health, in Boston.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228303128%22">Health affairs (Project Hope)</searchLink> [Health Aff (Millwood)] 2015 Jul; Vol. 34 (7), pp. 1234-40.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Project+Hope%22">Project Hope </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8303128 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2694-233X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202782715%22">02782715 </searchLink><i>NLM ISO Abbreviation: </i>Health Aff (Millwood) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26135209
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1377/hlthaff.2014.1274
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1234
    Titles:
      – TitleFull: Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kohli MA
      – PersonEntity:
          Name:
            NameFull: Farkouh RA
      – PersonEntity:
          Name:
            NameFull: Maschio MJ
      – PersonEntity:
          Name:
            NameFull: McGarry LJ
      – PersonEntity:
          Name:
            NameFull: Strutton DR
      – PersonEntity:
          Name:
            NameFull: Weinstein MC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2015 Jul
              Type: published
              Y: 2015
          Identifiers:
            – Type: issn-electronic
              Value: 2694-233X
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Health affairs (Project Hope)
              Type: main
ResultId 1